Drug Approval | April 28, 2026
AbbVie seeks FDA nod for subcutaneous SKYRIZI induction in Crohn’s disease
The submission is backed by positive results from the Phase 3 AFFIRM study
The submission is backed by positive results from the Phase 3 AFFIRM study
This study evaluated a difficult-to-treat Crohn's disease patient population
Duvakitug was well tolerated and safety was consistent with the induction study
Updated indication expands treatment options for patients with ulcerative colitis and Crohn’s disease when tumor necrosis factor (TNF) blockers are clinically inadvisable
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Subscribe To Our Newsletter & Stay Updated
